

Table 2: Comparison of Best Corrected Visual Acuity between arms at 12 and 52 weeks

Primary Outcome: BCVA	Mean (SD); N		Change from Baseline Mean (SE)		Adjusted difference between arms (95% CI)	p-value
	PRP	Aflibercept	PRP	Aflibercept		
Baseline	81.9 (8.0); 116	80.9 (8.3); 116	-	-	-	-
At 12-weeks						
ITT	81.3 (7.8); 101	82.6 (9.6); 109	-0.8 (0.4)	1.4 (0.5)	2.1 (0.5, 3.7) ¹	0.010
PP	81.3 (7.9); 99	82.7 (9.7); 102	-0.9 (0.4)	1.5 (0.6)	2.3 (0.6, 3.9) ²	0.007
At 52-weeks						
ITT	79.1 (9.7); 104	82.4 (10.1); 105	-3.0 (0.7)	1.1 (0.6)	3.9 (2.3, 5.6) ¹	<0.0001
PP	79.3 (9.3); 102	82.6 (10.1); 98	-2.9 (0.7)	1.3 (0.6)	4.0 (2.4, 5.7) ²	<0.0001

¹The LME model incorporates 221 (109 PRP and 112 aflibercept) participants with BCVA at either 12 or 52 weeks.

²The LME model incorporates 210 (106 PRP and 104 aflibercept) participants who have BCVA at either 12 or 52 weeks.